Anup Y Parikh, Robert Masi, Billel Gasmi, Ken-Ichi Hanada, Maria Parkhurst, Jared Gartner, Sivasish Sindiri, Todd Prickett, Paul Robbins, Nikolaos Zacharakis, Mike Beshiri, Kathleen Kelly, Steven A Rosenberg, James C Yang
Adoptive cell transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete responses in some patients with common epithelial cancers but does so infrequently. A better understanding of T-cell responses to neoantigens and tumor-related immune evasion mechanisms requires having the autologous tumor as a reagent. We investigated the ability of patient-derived tumor organoids (PDTO) to fulfill this need and evaluated their utility as a tool for selecting T-cells for adoptive cell therapy. PDTO established from metastases from patients with colorectal, breast, pancreatic, bile duct, esophageal, lung, and kidney cancers underwent whole exomic sequencing (WES), to define mutations...
June 27, 2023: Cancer Immunology, Immunotherapy: CII